Octanate Lv (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate Lv, is a Factor VIII concentrate presented as a solution for injection for intravenous use. It treats hemophilia A (congenital factor VIII deficiency) in patients requiring replacement therapy and is used under medical supervision to manage bleeding episodes and provide prophylactic coverage.

GNH USA supplies Octanate Lv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across all markets.

Octanate Lv provides factor VIII replacement for the intrinsic coagulation pathway in hemophilia A. - Hemophilia A (congenital factor VIII deficiency): restores deficient factor VIII to achieve hemostasis and reduce bleeding frequency. - Surgical procedures in hemophilia A patients: supplies adequate factor VIII levels to maintain hemostasis during and after surgery. - Trauma‑related bleeding in hemophilia A: rapidly replaces factor VIII to control acute hemorrhage.

Octanate Lv may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Infusion‑related reactions: fever, chills, or flushing during or shortly after administration. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Arthralgia: joint pain in patients with pre‑existing joint disease.

Serious or Rare Side Effects: - Development of inhibitory antibodies: neutralizing factor VIII and reducing efficacy. - Anaphylactic or severe allergic reactions: respiratory distress, hypotension, or urticaria. - Thromboembolic events: unexpected clot formation. - Transmission of blood‑borne pathogens: rare viral infection risk.

Before using Octanate Lv, healthcare professionals should consider several safety precautions. - Monitor for inhibitor development: test for anti‑factor VIII antibodies regularly. - Assess for allergic reactions: observe for signs of hypersensitivity during infusion. - Use cautiously in patients with cardiovascular disease: risk of thrombosis may be increased. - Avoid in individuals with known hypersensitivity to plasma‑derived products: contraindicated. - Do not mix with incompatible solutions: ensure proper diluent is used. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate Lv can interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use of bypassing agents (e.g., activated prothrombin complex concentrates) may increase thrombotic risk. - High‑dose anticoagulants (warfarin, heparin) may diminish the hemostatic effect of factor VIII. - Simultaneous administration of other plasma‑derived products may raise the risk of viral transmission.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy may alter inhibitor formation; monitor antibody levels. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase bleeding tendency despite replacement. - Combination with other clotting factor concentrates may require dose adjustments to avoid excess coagulation.